Adherence to therapy of patients with inflammatory bowel diseases


Cite item

Full Text

Abstract

Inflammatory bowel diseases are autoimmune systemic forms of pathology. The concept of continuous life-long drug intake is a cornerstone in their therapy. The review presents the factors that reduce patients adherence to treatment and ways to improve it. They include informing the patient about the disease and treatment, selection of individual therapy regimen, consolidation of achievements, provision of social support and interaction with other specialists.

About the authors

A I Parfenov

A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of Moscow

Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника Moscow, Russia

A V Kagramanova

A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of Moscow

к.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника Moscow, Russia

A F Babayan

A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of Moscow

врач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника Moscow, Russia

O V Knyazev

A.S. Loginov Moscow Clinical Scientific Center of the Department of Health of Moscow

д.м.н., зав. отд-нием воспалительных заболеваний кишечника Moscow, Russia

References

  1. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017 Oct;15(4):434-45. doi: 10.5217/ir.2017.15.4.434. Epub 2017 Oct 23. Review.
  2. Cramer J.A, Roy A, Burrell A, Fairchild C.J, Fuldeore M.J, Ollendorf D.A, Wong P.K. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
  3. Sackett D.L, Haynes R.B. Compliance with therapeutic regimens. Baltimore: The Johns Hopkins University Press; 1976.
  4. Vrijens B, De Geest S, Hughes D.A, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. doi: 10.1111/j.1365-2125.2012.04167.x
  5. Jackson C.A, Clatworthy J, Robinson A, Horne R. Factors associated with non - adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525-39. doi: 10.1038/ajg.2009.685
  6. Kawakami A, Tanaka M, Nishigaki M, et al. Relationship between non - adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol. 2013;48:1006-15. doi: 10.1007/s00535-012-0721-x
  7. Kim S.B, Kim K.O, Jang B.I, et al. Patients’ beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 2016;31:575-80. doi: 10.1111/jgh.13155
  8. Spekhorst L.M, Hummel T.Z, Benninga M.A, van Rheenen P.F, Kindermann A. Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62:264-70. doi: 10.1097/MPG.0000000000000924
  9. Jeganathan J, Lee C.H, Rahme A, et al. Medication adherence in transitional inflammatory bowel disease patients: a multicenter pilot study. J Gastroenterol Hepatol. 2014;29:111.
  10. Selinger C, Robinson A, Leong R. Non - adherence to inflammatory bowel disease maintenance medication: extent and predictors. J Gastroenterol Hepatol. 2011;26:116.
  11. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-33. doi: 10.1097/MIB.0b013e31828132cb
  12. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
  13. Khan N, Abbas A.M, Bazzano L.A, Koleva Y.N, Krousel-Wood M. Long - term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-64. doi: 10.1111/apt.12013
  14. Van der Have M, Oldenburg B, Kaptein A.A, et al. Non - adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis. 2016;10:549-55. doi: 10.1093/ecco-jcc/jjw002
  15. Kane S, Shaya F. Medication non - adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-4. doi: 10.1007/s10620-007-9968-0
  16. Hommel K.A, Davis C.M, Baldassano R.N. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008;33:867-74. doi: 10.1093/jpepsy/jsn022
  17. Horváth G, Farkas K, Hollósi R, et al. Is there any association between impaired health - related quality of life and non - adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol. 2012;47:1298-303. doi: 10.3109/00365521.2012.703233
  18. Perry J, Chen A, Kariyawasam V, Choong C, Teh W.L, Mitrev N, Kohler F, Leong R.W.L. Medication non - adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018 Oct;16(4):571-8. doi: 10.5217/ir.2018.00033
  19. Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther. 2013;38:531-8. doi: 10.1111/apt.12396
  20. Cramer J.A, Scheyer R.D, Mattson R.H. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-10.
  21. Fong S, Ward M.G, Nasr I, et al. PWE-111 higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence. Gut. 2014;63(Suppl 1):A173.
  22. Gifford A.E, Berg A.H, Lahiff C, Cheifetz A.S, Horowitz G, Moss A.C. A random urine test can identify patients at risk of mesalamine non - adherence: a prospective study. Am J Gastroenterol. 2013;108:249-55. doi: 10.1038/ajg.2012.419
  23. Andrade S.E, Kahler K.H, Frech F, Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-74. doi: 10.1002/pds.1230
  24. Nguyen T.M, La Caze A, Cottrell N. What are validated selfreport adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427-45. doi: 10.1111/bcp.12194
  25. Morisky D.E, Di Matteo M.R. Improving the measurement of selfreported medication nonadherence: final response. J Clin Epidemiol. 2011;64:262-3.
  26. Trindade A.J, Ehrlich A, Kornbluth A, Ullman T.A. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604. doi: 10.1002/ibd.21310
  27. Kane S, Becker B, Harmsen W.S, Kurian A, Morisky D.E, Zinsmeister A.R. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012;107:154-60. doi: 10.1038/ajg.2011.317
  28. Selinger C.P, Eaden J, Jones D.B, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2199-206. doi: 10.1097/MIB.0b013e31829ed8a6
  29. Moss A.C, Lillis Y, Edwards George J.B, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014;109:1850-5. doi: 10.1038/ajg.2014.158
  30. Waters B.M, Jensen L, Fedorak R.N. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005;19:235-44.
  31. Tiao D.K, Jeganathan J, Chen A., et al. Impact of targeted pharmacist counselling intervention on IBD medication adherence. J Gastroenterol Hepatol. 2014;29:106.
  32. Kripalani S, Yao X, Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50. doi: 10.1001/archinte.167.6.540
  33. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-3.
  34. Dignass A.U, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-9.
  35. Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi - center trial. Inflamm Bowel Dis. 2017;23:822-32. doi: 10.1097/MIB.0000000000001065
  36. Fenerty S.D, West C, Davis S.A, Kaplan S.G, Feldman S.R. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127-35. doi: 10.2147/PPA.S26314
  37. Greenley R.N, Gumidyala A.P, Nguyen E, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflamm Bowel Dis. 2015;21:2649-57. doi: 10.1097/MIB.0000000000000530
  38. Cook P.F, Emiliozzi S, El-Hajj D, Mc Cabe M.M. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns. 2010;81:182-6. doi: 10.1016/j.pec.2009.12.010
  39. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web - guided ‘Constant - care’ approach. Gut. 2010;59:1652-61. doi: 10.1136/gut.2010.220160
  40. Moshkovska T, Stone M.A, Smith R.M, Bankart J, Baker R, Mayberry J.F. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17:1874-81. doi: 10.1002/ibd.21570
  41. Hommel K.A, Herzer M, Ingerski L.M, Hente E, Denson L.A. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011;53:435-9. doi: 10.1097/MPG.0b013e3182203a91
  42. Hommel K.A, Hente E.A, Odell S, et al. Evaluation of a groupbased behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:64-9. doi: 10.1097/MEG.0b013e32834d09f1
  43. Aguas Peris M, Del Hoyo J, Bebia P, et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis. 2015;21:392-9. doi: 10.1097/MIB.0000000000000241
  44. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self - managed webbased solution in mild - to - moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276-85. doi: 10.1097/MIB.0000000000000199
  45. Cross R.K, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2012;18:1018-25. doi: 10.1002/ibd.21795
  46. Hommel K.A, Hente E, Herzer M, Ingerski L.M, Denson L.A. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol. 2013;25:469-73. doi: 10.1097/MEG.0b013e32835c2a1b

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies